放射治疗激活的 NBTXR3 用于治疗局部晚期或临界可切除胰腺癌
局部晚期或交界性可切除胰腺导管腺癌放疗激活 NBTXR3 的 I 期研究
To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
研究概览
地位
详细说明
PRIMARY OBJECTIVE:
• To determine the recommended phase II dose (RP2D) of NBTXR3 activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma.
SECONDARY OBJECTIVES:
- To evaluate the safety and feasibility of NBTXR3 intratumoral injection activated by radiotherapy in locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate the anti-tumor response of NBTXR3 intratumoral injection activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate time-to-event outcomes in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
EXPLORATORY OBJECTIVES:
- To evaluate the body kinetic profile of intratumorally injected NBTXR3.
- To evaluate time to event outcomes for subjects with clinical staging of locally advanced, unresectable disease.
- To evaluate resectability conversion rates.
- To evaluate surgical outcomes in subjects who undergo surgery after radiation therapy.
- To associate radiomic measurements with outcomes.
- To evaluate biomarkers of response in subjects treated with NBTXR3/RT.
OUTLINE: This is a dose-escalation study of NBTXR3.
Patients receive NBTXR3 intratumorally (IT) on day 1. Patients then undergo 15 fractions of intensity modulated radiation therapy (IMRT) between days 15-43 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Texas
-
Houston、Texas、美国、77030
- M D Anderson Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study 2. Age ≥ 18 years 3. Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features:
-
Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
-
Age ≥ 18 years
-
Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features: i. Occlusion of the SMV or PV that is not amenable to reconstruction ii. Tumor interface of the superior mesenteric artery or celiac axis ≥ 180° iii. Involvement of the hepatic artery that is not amenable to reconstruction iv. Involvement of the aorta
-
Has had a 4-month course (± 2-months) of chemotherapy for PDAC without radiographic evidence of distant metastatic disease. Following chemotherapy regimens are allowed:
- gemcitabine/nab-paclitaxel
- gemcitabine/capecitabine
- gemcitabine/cisplatin
- gemcitabine
- FOLFOX
- FOLFIRINOX
-
Amenable to undergo the endoscopic ultrasound guided injection of NBTXR3 as per investigator or treating physician.
-
Has a target lesion in the pancreas that is identifiable on cross sectional imaging by repeated measurements (via RECIST 1.1) at the same anatomical location
a. Nodal disease only is not allowed.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
-
Laboratory Values at screening:
- Hemoglobin ≥ 8.0 g/dL
- Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
- Platelet Count ≥ 100,000/mm3
- Creatinine ≤ 1.5 x upper limit of normal (ULN)
- Total Bilirubin ≤ 2.0 mg/dL
- AST / ALT ≤ 3.0 x upper limit of normal (ULN)
- Serum albumin ≥ 3.0 g/dL
-
Negative pregnancy test ≤ 7 days prior to NBTXR3 injection in all females of child-bearing potential
-
If participant has a history of prior duodenal or biliar plastic stent, it should be replaced with a metal stent ≥ 1 week prior to Study Day 1.
Exclusion Criteria:
-
Prior radiation therapy to the upper abdomen
-
Prior surgical resection of pancreatic tumor
-
Diagnosis other than pancreatic ductal adenocarcinoma. All other histologic types (i.e., adenosquamous, cystadenocarcinoma, etc.) are not eligible to participate on this study.
-
LAPC or BRPC with radiographic evidence of distant metastasis at screening.
-
Has received any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol (i.e. chemotherapies included in Inclusion #4)
-
Known uncontrolled (Grade ≥ 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
-
Known contraindication to iodine-based or gadolinium-based IV contrast
-
Active malignancy, in addition to pancreatic cancer, with the exception of basal cell carcinoma of the skin definitively treated and relapse free within at least 1 year from diagnosis
-
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
-
Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system <6 months prior to screening
-
Known active, uncontrolled (high viral load) HIV or hepatitis B or hepatitis C infection
a. Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible.
-
Female patients who are pregnant or breastfeeding
-
Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly
-
Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment (NBTXR3, radiation therapy)
Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity. |
Undergo radiation therapy
其他名称:
Given IT
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
推荐的 II 期剂量 (RP2D)
大体时间:长达 1 年
|
长达 1 年
|
|
|
Dose-limiting toxicities
大体时间:4 weeks after last radiation dose
|
Any grade >= 3 adverse event related to NBTXR3 and/or radiation therapy. Any toxicity (grade >= 3) that is at least possibly related to study drug (NBTXR3) is a DLT. Adverse events will be scored based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0). |
4 weeks after last radiation dose
|
|
Maximum tolerated dose (MTD)
大体时间:Up to 1 year
|
MTD will be determined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate 30%. |
Up to 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
无进展生存期 (PFS)
大体时间:从 NBTXR3 注射到局部复发、局部进展、远处进展或任何原因导致的死亡,以先发生者为准,评估长达 1 年
|
从 NBTXR3 注射到局部复发、局部进展、远处进展或任何原因导致的死亡,以先发生者为准,评估长达 1 年
|
|
|
总生存期(OS)
大体时间:从 NBTXR3 注射到全因死亡或 EoS,以先发生者为准,评估长达 1 年
|
从 NBTXR3 注射到全因死亡或 EoS,以先发生者为准,评估长达 1 年
|
|
|
Determination of the feasibility of NBTXR3 injection in pancreas
大体时间:Up to 1 year
|
Feasibility refers to the ability to do intratumoral injection of NBTXR3. The outcome for each patient would be "feasible" or "not feasible." |
Up to 1 year
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
接受NBTXR3/放疗后接受手术切除的局部晚期受试者比例(R3/RT)
大体时间:长达 1 年
|
长达 1 年
|
|
|
Presence of hafnium
大体时间:Up to 1 year
|
Will evaluation of the time-course dependent presence of hafnium in blood and urine following NBTXR3 intratumoral injection. |
Up to 1 year
|
|
Disease control rate
大体时间:6 months
|
Defined as the proportion of patients without progression 6 months post NBTXR3 injection. |
6 months
|
|
Resection status
大体时间:Up to 1 year
|
Resection status as assessed macroscopically by surgeon R0- Macroscopically complete tumor removal with negative microscopic surgical margins, R1- Macroscopically complete tumor removal with positive microscopic margins (any or all), and R2- Macroscopically incomplete tumor removal with known or suspected residual gross disease. |
Up to 1 year
|
合作者和调查者
调查人员
- 首席研究员:Eugene J Koay、M.D. Anderson Cancer Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.